Please find below and/or attached an Office communication concerning this application or proceeding.
**Office Action Summary**

--- The MAILING DATE of this communication appears on the cover sheet with the correspondence address ---

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHSOEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) □ Responsive to communication(s) filed on ______.
2a) □ This action is FINAL. 2b) □ This action is non-final.
3) □ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) □ Claim(s) 1-30 is/are pending in the application.
   4a) Of the above claim(s) ______ is/are withdrawn from consideration.
5) □ Claim(s) ______ is/are allowed.
6) □ Claim(s) ______ is/are rejected.
7) □ Claim(s) ______ is/are objected to.
8) □ Claim(s) 1-30 are subject to restriction and/or election requirement.

**Application Papers**

9) □ The specification is objected to by the Examiner.
10) □ The drawing(s) filed on ______ is/are: a) □ accepted or b) □ objected to by the Examiner.

   Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
   Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
    a) □ All  b) □ Some  c) □ None of:
    1. □ Certified copies of the priority documents have been received.
    2. □ Certified copies of the priority documents have been received in Application No. ______.
    3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

   * See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1) □ Notice of References Cited (PTO-892)
2) □ Notice of Drawn/aperson's Patent Drawing Review (PTO-948)
3) □ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
   Paper No(s)/Mail Date ______.
4) □ Interview Summary (PTO-413)
   Paper No(s)/Mail Date ______.
5) □ Notice of Informal Patent Application (PTO-152)
6) □ Other: ____.
1. Claims 1-30 are pending.

2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
   
   I. Claims 1–18 and 21-30, drawn to methods of treating neoplastic diseases or disorders with a CD40-specific agent in combination with a CD20-specific agent, classified in Class 424/ 130.1.

   II. Claims 19-20 drawn to compositions comprising a CD40-specific agent in combination with a CD20-specific agent, classified in Class 424, 141.1.


3. Inventions II / I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)).

   In the instant case, the products as claimed can be used in a materially different processes such as in vitro screening assays and bioassays as well as detection assays.

   Alternatively, there are a number of agents other than those set forth in Groups II that have been used for the treatment of the neoplastic diseases or disorders targeted in Groups I and III.

4. Because these inventions are distinct for the reasons given above and the search required for any group from Groups I-III is not required for any other group from Groups I-III and Groups I-III have acquired a separate status in the art as shown by their divergent subject matter, restriction for examination purposes as indicated is proper.

5. In addition to selecting a Group from above, applicant is required to make a species election as well.

   (A) This application contains claims directed to the following patentably distinct species of the claimed inventions of Groups I - III:

   wherein the CD40-specific agent is selected from a CD40-specific antibody or those disclosed on pages 19-21 of the instant specification
   AND
   wherein the CD20-specific agent is selected from a CD20-specific antibody or those disclosed on page 21 of the instant specification.

   These species are distinct because their structures, interactions, modes of action are different. Therefore, they are patentably distinct. These various agents and molecules do not share a substantial structural feature essential to a common utility.
Applicant is required to elect a specific CD40-specific agent AND a CD20-specific agent.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

6. **IN ADDITION, if applicant elects Group I, AND a species from Section 5:**
   - this application contains claims directed to the following patently distinct species of the claimed invention of Group I: wherein the neoplastic disease or disorder is selected from claims 5-9 or Table 1 disclosed on pages 35-36 of the instant specification.

   These neoplastic disorders differ in etiologies and therapeutic endpoints. Therefore, they are patently distinct.

   Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

7. **IN ADDITION, if applicant elects Group III, AND a species from Section 5:**
   - this application contains claims directed to the following patently distinct species of the claimed invention of Group I: wherein the autoimmune disease or disorder is selected from claims 22-23 or pages 36-37 of the instant specification.

   These autoimmune disorders differ in etiologies and therapeutic endpoints. Therefore, they are patently distinct.

   Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

8. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

   Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

   Should applicant traverse on the ground that the species are not patently distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.
9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

11. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

   In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

   Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.
12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

[Signature]
Phillip Gambel, PhD.
Primary Examiner
Technology Center 1600
September 28, 2005